Sarepta Therapeutics, based in Cambridge, Massachusetts, focuses on RNA-targeted therapeutics for rare diseases, particularly Duchenne muscular dystrophy, and has developed four approved products. The company employs 1,314 people and has about 40 programs in its pipeline.
SRPT has been in the news recently: Sarepta Therapeutics Inc. experienced a significant stock increase of 41.05% after the FDA recommended lifting a voluntary hold on its gene therapy drug, Elevidys, for Duchenne Muscular Dystrophy. Following this news, trading of Sarepta's shares was temporarily halted.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
